167 related articles for article (PubMed ID: 38231165)
1. Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing.
Shafer P; Leung WK; Woods M; Choi JM; Rodriguez-Plata CM; Maknojia A; Mosquera A; Somes LK; Joubert J; Manliguez A; Ranjan R; Burt B; Lee HS; Zhang B; Fuqua S; Rooney C; Leen AM; Hoyos V
Cytotherapy; 2024 Mar; 26(3):266-275. PubMed ID: 38231165
[TBL] [Abstract][Full Text] [Related]
2. Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations.
Shen M; Chen S; Han X; Hao Y; Wang J; Li L; Chen T; Wang B; Zou L; Zhang T; Zhang W; Han X; Wang W; Yu H; Li K; Liu S; Jin A
Cancer Immunol Immunother; 2024 Jun; 73(8):150. PubMed ID: 38832948
[TBL] [Abstract][Full Text] [Related]
3. Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
Plewa N; Poncette L; Blankenstein T
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822673
[TBL] [Abstract][Full Text] [Related]
4. Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers.
Li Q; Hu W; Liao B; Song C; Li L
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798537
[TBL] [Abstract][Full Text] [Related]
5. Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer.
Goldberg J; Qiao N; Guerriero JL; Gross B; Meneksedag Y; Lu YF; Philips AV; Rahman T; Meric-Bernstam F; Roszik J; Chen K; Jeselsohn R; Tolaney SM; Peoples GE; Alatrash G; Mittendorf EA
Cancer Res Commun; 2024 Feb; 4(2):496-504. PubMed ID: 38335301
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.
Chandarlapaty S; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Voi M; Gnant M; Hortobagyi G; Baselga J; Moynahan ME
JAMA Oncol; 2016 Oct; 2(10):1310-1315. PubMed ID: 27532364
[TBL] [Abstract][Full Text] [Related]
7. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.
Ade CM; Sporn MJ; Das S; Yu Z; Hanada KI; Qi YA; Maity T; Zhang X; Guha U; Andresson T; Yang JC
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37758652
[TBL] [Abstract][Full Text] [Related]
8. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Sueta A; Tomiguchi M; Murakami K; Omoto Y; Iwase H
BMC Cancer; 2017 Nov; 17(1):786. PubMed ID: 29166868
[TBL] [Abstract][Full Text] [Related]
10. Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.
Dillard P; Casey N; Pollmann S; Vernhoff P; Gaudernack G; Kvalheim G; Wälchli S; Inderberg EM
Oncoimmunology; 2021; 10(1):1936757. PubMed ID: 34235003
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
[TBL] [Abstract][Full Text] [Related]
12. Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Omoto Y; Iwase H
Transl Oncol; 2017 Oct; 10(5):766-771. PubMed ID: 28778025
[TBL] [Abstract][Full Text] [Related]
13. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
14. Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
Transl Res; 2015 Dec; 166(6):540-553.e2. PubMed ID: 26434753
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
[TBL] [Abstract][Full Text] [Related]
16. T-cell Receptors Engineered
Sharma P; Harris DT; Stone JD; Kranz DM
Cancer Immunol Res; 2019 Dec; 7(12):2025-2035. PubMed ID: 31548259
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA.
Chandran SS; Ma J; Klatt MG; Dündar F; Bandlamudi C; Razavi P; Wen HY; Weigelt B; Zumbo P; Fu SN; Banks LB; Yi F; Vercher E; Etxeberria I; Bestman WD; Da Cruz Paula A; Aricescu IS; Drilon A; Betel D; Scheinberg DA; Baker BM; Klebanoff CA
Nat Med; 2022 May; 28(5):946-957. PubMed ID: 35484264
[TBL] [Abstract][Full Text] [Related]
18. High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies.
Çınar Ö; Brzezicha B; Grunert C; Kloetzel PM; Beier C; Peuker CA; Keller U; Pezzutto A; Busse A
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330762
[TBL] [Abstract][Full Text] [Related]
19. A minority of T cells recognizing tumor-associated antigens presented in self-HLA can provoke antitumor reactivity.
Roex MCJ; Hageman L; Veld SAJ; van Egmond E; Hoogstraten C; Stemberger C; Germeroth L; Einsele H; Falkenburg JHF; Jedema I
Blood; 2020 Jul; 136(4):455-467. PubMed ID: 32483595
[TBL] [Abstract][Full Text] [Related]
20. PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer.
van Amerongen RA; Tuit S; Wouters AK; van de Meent M; Siekman SL; Meeuwsen MH; Wachsmann TLA; Remst DFG; Hagedoorn RS; van der Steen DM; de Ru AH; Verdegaal EME; van Veelen PA; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2023; 14():1121973. PubMed ID: 37026005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]